AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.82 |
Market Cap | 4.78M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.88 |
PE Ratio (ttm) | 4.01 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.12 |
Volume | 9,460 |
Avg. Volume (20D) | 27,603 |
Open | 3.33 |
Previous Close | 3.27 |
Day's Range | 3.33 - 3.58 |
52-Week Range | 2.32 - 7.22 |
Beta | undefined |
About SNPX
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and N...
Analyst Forecast
According to 1 analyst ratings, the average rating for SNPX stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 296.70% from the latest price.